The frequency of balanced translocations in MDS is estimated to be less than 10% with most translocations involving MLL, EVI1 and DEK/NUP214 [21], which suggests that conventional cytogenetics and aCGH are complementary assays in the clinical workup of the myeloid disorders. The gene discussed is RUNX1; the disease is myelodysplastic syndrome.